Copy

Special edition on Innovation and Technology Transfer

From the editor

“The rewards for biotechnology are tremendous - to solve disease, eliminate poverty, age gracefully. It sounds so much cooler than Facebook”
George M. Church, Broad Institute, Harvard


Barcelona has turned into a thriving player in the European life science and healthcare start-up landscape. According to Biocat there are 335 biotech companies based in Catalonia. Each year more than 20 new bio ventures are created and investments of venture capital have surpassed 200 M€ per year. These numbers situate Barcelona and Catalonia within the top 15 life science hotspots in Europe.

Building an adequate biotech ecosystem has taken 20 years. The basis has been a strong local scientific community and the empowerment of technology transfer offices in research centres and universities. Other missing elements of the ecosystem were added subsequently: patent lawyers, bio executives, venture capitalists, talent-hunters, bringing local pharmaceutical companies on track and lowering the administrative and legal hurdles to create a spin-off from a public research entity.

Researchers from the centres at the Barcelona Biomedical Research Park (PRBB) have created 12 spin-off companies over the years, all still running and successful. Recent success stories include Pulmobiotics, a CRG spin-off that has raised 2 M€ as seed capital to develop live biotherapeutics for respiratory diseases, and Integra Therapeutics, a MELIS-UPF spin-off that just closed a 6M€ seed round investment to engineer next-generation gene writing tools to cure diseases.

Today, an innovative scientist at the centres of the PRBB finds competent consultants within their organisation to patent inventions and subsequently license the intellectual property to companies. And creating a start-up company in Catalonia is today less challenging than only 5 years ago. Finally, we have reached a point where innovations can pop-up safely and scale-up more efficiently. So, if you are an innovator, go for it!

Reimund Fickert, PRBB

#
PRBBInnovation 

 

Top picks

SCIENTIFIC LIFE 


1M for Flomics Biotech and its cancer diagnostics kit


Flomics Biotech, a CRG and UPF startup, has closed its first seed investment round of 1,000,000 euros, which will allow them to continue developing their cancer detection and diagnosis proposal.
 
SCIENTIFIC LIFE 


4.5M€ for the development of state-of-the-art genetic engineering technologies


The UPF spin-off Integra Therapeutics received funds from different investors to finish its technological prototype and promote the project over the next two years.
 
SCIENTIFIC LIFE 


Pulmobiotics: transforming a pathogen to fight lung disease


We talk to Maria Lluch, a CRG researcher who, in the midst of the COVID-19 pandemic, has co-funded the Pulmobiotics spin-off, which aims to develop therapeutic applications for lung diseases.
 
SCIENTIFIC LIFE 


Sira Mogas (DCEXS-UPF): “We have found a way to create complex cellular sensors that can be easily used outside of the laboratory”


We talked with Sira Mogas and Javier Macía, from DCEXS-UPF, about the technology they have developed for printing cellular devices on a big scale.
 
SCIENTIFIC LIFE 


A strategic agreement to accelerate the development of new drugs


The CRG and the drug identification company Chemotargets, a spin-off of IMIM, have joined forces to promote the development of new therapies for different diseases, such as cancer or fibrosis.
 

Intervals

Innovation and Techonology Transfer should be an essential part of the scientific research process, and something young researchers must learn about and be familiar with. For this reason, from the PRBB we have started to offer the following course through Intervals, our continuous professional development program, free of charge for all PRBB residents:
 

Business opportunities in science and beyond

This course explains the basics about business plans, patents, venture capital and opportunities in the life science sector.

Fresh knowledge that any research-related person should get a hint of.
 

-  "Business opportunities" participant

A general overview of what is necessary for progressing from academia to market.

-  "Business opportunities" participant

Stay tuned!

Our next and last special edition will focus on mental wellbeing in academia, a topic of ever growing interest - and one the COvid19 pandemic has only made more visible. How can we promote a healthy working environment where researchers can fulfil their full potential while ensuring that this does not take a toll on their mental health?

We will discuss this our next newsletter - make sure you subscribe to get it in your inbox, and help us spread the word!

#JoinEllipse

Instagram
Twitter
Flickr
LinkedIn
Facebook
YouTube
Copyright © 2022 PRBB, All rights reserved.


Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.

Email Marketing Powered by Mailchimp